Crispr Therapeutics Company Insiders

Crispr Therapeutics' latest congressional trading

Crispr Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1288) % which means that it has lost $0.1288 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1971) %, meaning that it created substantial loss on money invested by shareholders. Crispr Therapeutics' management efficiency ratios could be used to measure how well Crispr Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 07/22/2025, Return On Tangible Assets is likely to drop to -0.17. In addition to that, Return On Capital Employed is likely to grow to -0.21. As of 07/22/2025, Total Current Liabilities is likely to drop to about 66.5 M. In addition to that, Liabilities And Stockholders Equity is likely to drop to about 1.4 BAs of 07/22/2025, Common Stock Shares Outstanding is likely to drop to about 60.3 M. In addition to that, Net Loss is likely to grow to about (555.9 M)

Crispr Therapeutics Workforce Comparison

Crispr Therapeutics Insider Trading History

Crispr Therapeutics Notable Stakeholders

The success or failure of an entity such as Crispr Therapeutics often depends on how effective the management is. Crispr Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Crispr management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Crispr management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.